Fibroblast Growth Factor 23 describes how FGF23 was initially identified as a bone-derived factor targeting the kidney. This reference then defines the exciting research in recent years how a much wider spectrum of sources, targets and functions have been identified, showing that different FGF23 effects require distinct signaling receptors and mediators that differ among target tissues.

This reference reaches a wide academic audience with a broad interest in biomedical sciences, including:

• Endocrinology: FGF23 initially identified as a bone-derived factor targeting the kidney
• Physiology: FGF23 as a regulator of phosphate metabolism and beyond
• Cell Biology: Mechanistic FGF23 research revealed novel concepts of FGF receptor signaling
• Biochemistry: Molecular crosstalk between FGF23 and klotho, from structure and binding to signal transduction
• Pharmacology: FGF23 and its receptors as potential drug targets to treat or prevent diseases, such as CKD, heart failure or COPD
• Basic Research: Cell culture and animal models as well as novel assays to study FGF23 production and effects
• Nephrology: FGF23 as a biomarker and cause for CKD and associated pathologies
• Internal Medicine: FGF23 as a biomarker and cause for various diseases involving the kidney, heart, lung and liver